Urogenit Tract Infect.  2017 Dec;12(3):95-102. 10.14777/uti.2017.12.3.95.

Management of Antibiotic-Resistant Acute Pyelonephritis

• Lee HN
• Yoon H

• KMID: 2400217
• DOI: http://doi.org/10.14777/uti.2017.12.3.95

Abstract

Acute pyelonephritis (APN) is a common urinary tract infection that affects a large proportion of women. Although antimicrobial therapy is a successful treatment in most cases, empirically, antibiotic resistance has emerged as a serious issue, including high resistance rate of fluoroquinolone and the advent of extended-spectrum β-lactamase (ESBL)-producing organisms. Several agents can be considered for the management of antibiotic resistant APN. Fosfomycin trometamol is effective in treating ESBL-producing bacterial infection. Oral trimethoprim/sulfamethoxazole, β-lactam agents, such as cephalosporin, and fluoroquinolone can be regarded as appropriate agents if pathogen is susceptible. Carbapenem, such as imipenem, meropenem, and doripenem, is one of the best and widely used agents for treating antibiotic resistant APN. However, there have recently been concerns regarding the increased rates of resistance to carbapenems. Daptomycin, linezolid, and tigecycline can be considered as solutions to antibiotic resistant organisms. Antibiotic resistant APN should be treated as other systemic infections to prevent antibiotic overuse with proper treatment duration considering carbapenem-saving strategy.

Keyword

Pyelonephritis; Drug resistance, microbial; Urinary tract infections

MeSH Terms

Bacterial Infections
Carbapenems
Daptomycin
Drug Resistance, Microbial
Female
Fosfomycin
Humans
Imipenem
Linezolid
Pyelonephritis*
Tromethamine
Urinary Tract Infections
Carbapenems
Daptomycin
Fosfomycin
Imipenem
Linezolid
Tromethamine

Reference

1.Shin J., Kim J., Wie SH., Cho YK., Lim SK., Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012. 18:169–75.

2.Lee SJ., Lee DS., Choe HS., Shim BS., Kim CS., Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother. 2011. 17:440–6.

3.World Health Organization. Report on infectious diseases 2000: overcoming antimicrobial resistance. Geneva: World Health Organization;2000.

4.Centers for Disease Control and Prevention. Prevention emerging infectious diseases [Internet]. Atlanta: Centers for Disease Control and Prevention;c1998. [cited 2016 Sep 2]. Available from:. https://stacks.cdc.gov/view/cdc/6695.

5.Picozzi S., Ricci C., Gaeta M., Macchi A., Dinang E., Paola G, et al. Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population? Urol Ann. 2013. 5:25–9.

6.Briongos-Figuero LS., Gómez-Traveso T., Bachiller-Luque P., Domínguez-Gil González M., Gómez-Nieto A., Palacios-Martín T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012. 66:891–6.

7.Lu PL., Liu YC., Toh HS., Lee YL., Liu YM., Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012. 40(Suppl):S37–43.

8.Akduman B., Akduman D., Tokgöz H., Erol B., Türker T., Ayoğlu F, et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology. 2011. 78:250–5.

9.Picozzi SC., Casellato S., Rossini M., Paola G., Tejada M., Costa E, et al. Extended-spectrum beta-lactamase-positive Escherichia coli causing complicated upper urinary tract infection: Urologist should act in time. Urol Ann. 2014. 6:107–12.

10.Boyle DP., Zembower TR. Epidemiology and management of emerging drug-resistant gram-negative bacteria: extended-spectrum -lactamases and beyond. Urol Clin North Am. 2015. 42:493–505.

11.van Nieuwkoop C., van't Wout JW., Assendelft WJ., Elzevier HW., Leyten EM., Koster T, et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infect Dis. 2009. 9:131.

12.Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999. 58(Suppl 2):11–8.

13.Tanaka M., Onodera Y., Uchida Y., Sato K., Hayakawa I. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother. 1997. 41:2362–6.

14.Navia MM., Ruiz J., Ribera A., de Anta MT., Vila J. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii. J Antimicrob Chemother. 1999. 44:743–8.

15.Linde HJ., Schmidt M., Fuchs E., Reischl U., Niller HH., Lehn N. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother. 2001. 45:1553–7.

16.Burchall JJ., Elwell LP., Fling ME. Molecular mechanisms of resistance to trimethoprim. Rev Infect Dis. 1982. 4:246–54.

17.Park H., Bradrick TD., Howell EE. A glutamine 67—> histidine mutation in homotetrameric R67 dihydrofolate reductase results in four mutations per single active site pore and causes substantial substrate and cofactor inhibition. Protein Eng. 1997. 10:1415–24.

18.Then RL. Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. Rev Infect Dis. 1982. 4:261–9.

19.Livermore DM. Antibiotic resistance in staphylococci. Int J Antimicrob Agents. 2000. 16(Suppl 1):S3–10.

20.Stapleton P., Wu PJ., King A., Shannon K., French G., Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother. 1995. 39:2478–83.

21.Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001. 119(2 Suppl):397S–404S.

22.Culebras E., Martínez JL. Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase. Front Biosci. 1999. 4:D1–8.

23.The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms—combined results of surveys in eight regions of the world. J Chemother. 1995. 7(Suppl 2):17–30.

24.Wagenlehner FM., Weidner W., Naber KG. Antibiotics in urology: new essentials. Urol Clin North Am. 2008. 35:69–79. vi.

25.Gupta K., Hooton TM., Naber KG., Wullt B., Colgan R., Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011. 52:e103–20.

26.McLuskey K., Cameron S., Hammerschmidt F., Hunter WN. Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavin-dependent mechanism. Proc Natl Acad Sci U S A. 2005. 102:14221–6.

27.Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003. 22(Suppl 2):79–83.

28.Veve MP., Wagner JL., Kenney RM., Grunwald JL., Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum -lactamase urinary tract infections. Int J Antimicrob Agents. 2016. 48:56–60.

29.Ode B., Haidl S., Hoffstedt B., Walder M., Ursing J. Fosfomycin versus ampicillin in the treatment of acute pyelonephritis. Chemioterapia. 1988. 7:96–100.

30.Patel SS., Balfour JA., Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997. 53:637–56.

31.Warren JW., Abrutyn E., Hebel JR., Johnson JR., Schaeffer AJ., Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999. 29:745–58.

32.Sanchez M., Collvinent B., Miró O., Horcajada JP., Moreno A., Marco F, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002. 19:19–22.

33.Czaja CA., Scholes D., Hooton TM., Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007. 45:273–80.

34.Jeon JH., Kim K., Han WD., Song SH., Park KU., Rhee JE, et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother. 2012. 56:3043–6.

35.Hammond ML. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother. 2004. 53(Suppl 2):ii7–9.

36.Papp-Wallace KM., Endimiani A., Taracila MA., Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011. 55:4943–60.

37.Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016. 3:15–21.

38.Boucher HW., Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007. 45:601–8.

39.Ramaswamy DP., Amodio-Groton M., Scholand SJ. Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series. BMC Urol. 2013. 13:33.

40.Jones RN., Johnson DM., Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 1996. 40:720–6.

41.Betriu C., Redondo M., Palau ML., Sánchez A., Gómez M., Culebras E, et al. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000. 44:1838–41.

42.Diekema DI., Jones RN. Oxazolidinones: a review. Drugs. 2000. 59:7–16.

43.Falagas ME., Lourida P., Poulikakos P., Rafailidis PI., Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014. 58:654–63.

44.Kaewpoowat Q., Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015. 14:335–42.